The use of rapid lateral flow antigen testing (LFT) for SARS-CoV-2 has been questioned1, 2, 3 with uncorroborated4 reports of poor LFT sensitivity. The debate surrounding the use of the Innova Lateral Flow SARS-CoV-2 Antigen Test in the UK risks confusing policy makers internationally and potentially stalling deployment of LFTs in other countries.5 As scientists and health professionals evaluating some of the world’s largest pilots of LFT, we wish to challenge those interpretations and clarify the evidence on how such testing might be used to detect SARS-CoV-2 in minutes and improve COVID-19 control measures.
Testing for SARS-CoV-2 is central to COVID-19 management and has relied on quantitative reverse transcriptase polymerase chain reaction (PCR) technology. PCR seeks the genetic code of the virus from nose or throat swabs and amplifies it over 30–40 cycles, doubling each cycle, enabling even miniscule, potentially single, copies to be detected. PCR is thus a powerful clinical test, specifically when a patient is, or was recently, infected with SARS-CoV-2. Fragments of RNA can linger for weeks after infectious virus has been cleared,6 often in people without symptoms or known exposures.7
However, for public health measures, another approach is needed. Testing to help slow the spread of SARS-CoV-2 asks not whether someone has RNA in their nose from earlier infection, but whether they are infectious today. It is a net loss to the health, social, and economic wellbeing of communities if post-infectious individuals test positive and isolate for 10 days. In our view, current PCR testing is therefore not the appropriate gold standard for evaluating a SARS-CoV-2 public health test.
Most people infected with SARS-CoV-2 are contagious for 4–8 days.7 Specimens are generally not found to contain culture-positive (potentially contagious) virus beyond day 9 after the onset of symptoms, with most transmission occurring before day 5.7, 8 This timing fits with the observed patterns of virus transmission (usually 2 days before to 5 days after symptom onset), which led public health agencies to recommend a 10-day isolation period.9 The short window of transmissibility contrasts with a median 22–33 days of PCR positivity (longer with severe infections and somewhat shorter among asymptomatic individuals).10 This suggests that 50–75% of the time an individual is PCR positive, they are likely to be post-infectious
Once SARS-CoV-2 replication has been controlled by the immune system, RNA levels detectable by PCR on respiratory secretions fall to very low levels when individuals are much less likely to infect others.13, 14, 15 The remaining RNA copies can take weeks, or occasionally months,16, 17 to clear, during which time PCR remains positive.7
A public health test for detecting someone who might be contagious is, by logical deduction, expected to have a sensitivity of around 30–40% versus PCR when testing a random sample of asymptomatic people in a steady-state outbreak.18 Furthermore, the asymmetry of RNA reflecting more infectiousness nearer to the time of exposure, means that the sensitivity of the ideal test of infectiousness when measured against PCR may vary across the epidemic curve, from as high as 50–60% when an outbreak is surging to 20–30% or less as infections decline.19
LFT and the UK testing programme have been criticised1, 2, 3, 5 for poor sensitivity in people without symptoms. In our view, these criticisms misinterpreted data from the interim report on the pilot of community testing in Liverpool, UK.20, 21 When paired LFT and PCR testing was done in Liverpool, the epidemic curve was declining.20 At this point, a priori one should expect a public health test that is highly sensitive for detecting infectious virus to show low overall sensitivity relative to PCR in people without symptoms or known exposures.